These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22537224)

  • 1. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
    Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
    Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
    Burkitt K; Ljungman M
    Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway.
    Landais I; Sobeck A; Stone S; LaChapelle A; Hoatlin ME
    Int J Cancer; 2009 Feb; 124(4):783-92. PubMed ID: 19048618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents.
    Wang GZ; Liu YQ; Cheng X; Zhou GB
    Cancer Sci; 2015 Jul; 106(7):902-8. PubMed ID: 25891850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-deficient cells.
    Jang SW; Kim JM
    Cell Cycle; 2022 Jul; 21(14):1468-1478. PubMed ID: 35506981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
    Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
    J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
    Chen P; Li J; Jiang HG; Lan T; Chen YC
    Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors.
    Chen CC; Kennedy RD; Sidi S; Look AT; D'Andrea A
    Mol Cancer; 2009 Apr; 8():24. PubMed ID: 19371427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
    Duan W; Gao L; Zhao W; Leon M; Sadee W; Webb A; Resnick K; Wu X; Ramaswamy B; Cohn DE; Shapiro C; Andreassen PR; Otterson GA; Villalona-Calero MA
    Transl Res; 2013 Mar; 161(3):156-64. PubMed ID: 23063585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine Has a Synergistic Anticancer Effect with Cisplatin via Inhibiting Fanconi Anemia Group D2 Protein Monoubiquitination in Hepatocellular Carcinoma Cells.
    Oda Y; Hidaka M; Suzuki A
    Biol Pharm Bull; 2017 Nov; 40(11):2005-2009. PubMed ID: 28855448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
    Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
    Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
    Kachnic LA; Li L; Fournier L; Willers H
    Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
    Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
    BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
    Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
    Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
    Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
    Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
    BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
    Pfäffle HN; Wang M; Gheorghiu L; Ferraiolo N; Greninger P; Borgmann K; Settleman J; Benes CH; Sequist LV; Zou L; Willers H
    Cancer Res; 2013 Oct; 73(20):6254-63. PubMed ID: 23966292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.